[1] Gaudana, R.; Jwala, J.; Boddu, S. H. S.; Mitra, A. K. Recent perspectives in ocular drug delivery. Pharm. Res. 2009, 26, 1197–1216.

[2] Diebold, Y.; Calonge, M. Applications of nanoparticles in ophthalmology. Prog. Retin. Eye Res. 2010, 29, 596–609.

[3] Liu, S.; Jones, L.; Gu, F. X. Nanomaterials for ocular drug delivery. Macromol. Biosci. 2012, 12, 608–620.

[4] Cho, H. K.; Cheong, I. W.; Lee, J. M.; Kim, J. H. Polymeric nanoparticles, micelles and polymersomes from amphiphilic block copolymer. Korean. J. Chem. Eng. 2010, 27, 731–740.

[5] Subbiah, R.; Veerapandian, M.; Yun, K. S. Nanoparticles: Functionalization and multifunctional applications in biomedical sciences. Curr. Med. Chem. 2010, 17, 4559–4577.

[6] Gavini, E.; Chetoni, P.; Cossu, M.; Alvarez, M. G.; Saettone, M. F.; Giunchedi, P. PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: In vitro/in vivo studies. Eur. J. Pharm. Biopharm. 2004, 57, 207–212.

[7] Yoncheva, K.; Vandervoort, J.; Ludwig, A. Development of mucoadhesive poly(lactide-co-glycolide) nanoparticles for ocular application. Pharm. Dev. Technol. 2011, 16, 29–35.

[8] Gupta, H.; Aqil, M.; Khar, R. K.; Ali, A.; Bhatnagar, A.; Mittal, G. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomed-nanotechnol. 2010, 6, 324–333.

[9] Lee, V. H. L. Review: New directions in the optimization of ocular drug delivery. J. Ocul. Pharmacol. 1990, 6, 157–164.

[10] Zimmer, A.; Kreuter, J. Microspheres and nanoparticles used in ocular delivery systems. Adv. Drug Deliv. Rev. 1995, 16, 61–73.

[11] Bazile, D.; Prud□homme, C.; Bassoullet, M. T.; Marlard, M.; Spenlehauer, G.; Veillard, M. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 1995, 84, 493–498.

[12] Dhar, S.; Gu, F. X.; Langer, R.; Farokhzad, O. C.; Lippard, S. J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 17356–17361.

[13] Dong, Y. and Feng, S.-S. In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for small-molecule drug chemotherapy. Biomaterials 2007, 28, 4154–4160.

[14] Esmaeili, F.; Ghahremani, M. H.; Ostad, S. N.; Atyabi, F.; Seyedabadi, M.; Malekshahi, M. R.; Amini, M.; Dinarvand, R. Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J. Drug Target. 2008, 16, 415–423.

[15] Gao, Y.; Sun, Y.; Ren, F.; Gao, S. PLGA-PEG-PLGA hydrogel for ocular drug delivery of dexamethasone acetate. Drug Dev. Ind. Pharm. 2010, 36, 1131–1138.

[16] Vega, E.; Egea, M. A.; Calpena, A. C.; Espina, M.; Garcia, M. L. Role of hydroxypropyl-β-cyclodextrin on freeze-dried and gamma-irradiated PLGA and PLGA-PEG diblock copolymer nanospheres for ophthalmic flurbiprofen delivery. Int. J. Nanomedicine 2012, 7, 1357–1371.

[17] Yang, J.; Yan, J.; Zhou, Z.; Amsden, B. G. Dithiol-PEG-PDLLA micelles: Preparation and evaluation as potential topical ocular delivery vehicle. Biomacromolecules 2014, 15, 1346–1354

[18] Verma, M. S.; Liu, S.; Chen, Y. Y.; Meerasa, A.; Gu, F. X. Size-tunable nanoparticles composed of Dextran-b-poly(d,l-lactide) for drug delivery applications. Nano. Res. 2012, 5, 49–61.

[19] Goodwin, A. P.; Tabakman, S. M.; Welsher, K.; Sherlock, S. P.; Prencipe, G.; Dai, H. Phospholipid-Dextran with a single coupling point: A useful amphiphile for functionalization of nanomaterials. J. Am. Chem. Soc. 2009, 131, 289–296.

[20] Ludwig, A. The use of mucoadhesive polymers in ocular drug delivery. Adv. Drug Deliv. Rev. 2005, 57, 1595–1639.

[21] Shaikh, R.; Raj Singh, T. R.; Garland, M. J.; Woolfson, A. D.; Donnelly, R. F. Mucoadhesive drug delivery systems. J. Pharm. Bioall. 2011, 3, 89–100.

[22] Khutoryanskiy, V. V. Advances in mucoadhesion and mucoadhesive polymers. Macromol. Biosci. 2011, 11, 748–764.

[23] du Toit, L. C.; Pillay, V.; Choonara, Y. E.; Govender, T.; Carmichael, T. Ocular drug delivery-A look towards nanobioadhesives. Expert Opin. Drug Deliv. 2011, 8, 71–94.

[24] Li, N.; Zhuang, C.; Wang, M.; Sui, C.; Pan, W. Low molecular weight chitosan-coated liposomes for ocular drug delivery: In vitro and in vivo studies. Drug Deliv. 2012, 19, 28–35.

[25] Mahmoud, A. A.; El-Feky, G. S.; Kamel, R.; Awad, G. E. A. Chitosan/sulfobutylether-beta-cyclodextrin nanoparticles as a potential approach for ocular drug delivery. Int. J. Pharm. 2011, 413, 229–236.

[26] Abdelbary, G. Ocular ciprofloxacin hydrochloride mucoadhesive chitosan-coated liposomes. Pharm. Dev. Technol. 2011, 8, 44–56.

[27] Li, N.; Zhuang, C.; Wang, M.; Sun, X.; Nie, S.; Pan, W. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int. J. Pharm. 2009, 379, 131–138.

[28] De Campos, A. M.; Sanchez, A.; Alonso, M. J. Chitosan nanoparticles: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm. 2001, 224, 159–168.

[29] Matsumoto, A.; Cabral, H.; Sato, N.; Kataoka, K.; Miyahara, Y. Assessment of tumor metastasis by the direct determination of cell-membrane sialic acid expression. Angew. Chem. Int. Edit. 2010, 49, 5494–5497.

[30] Matsumoto, A.; Sato, N.; Cabral, H.; Kataoka, K.; Miyahara, Y. Self-assembled molecular gate field effect transistor for label free sialic acid detection at cell membrane. Eurosensor XXIV Conference 2010, 5, 926–929.

[31] Matsumoto, A.; Sato, N.; Kataoka, K.; Miyahara, Y. Noninvasive sialic acid detection at cell membrane by using phenylboronic acid modified self-assembled monolayer gold electrode. J. Am. Chem. Soc. 2009, 131, 12022–12023.

[32] Ivanov, A. E.; Eccles, J.; Panahi, H. A.; Kumar, A.; Kuzimenkova, M. V.; Nilsson, L.; Bergenstahl, B.; Long, N.; Phillips, G. J.; Mikhalovsky, S. V.; et al. Boronate-containing polymer brushes: Characterization, interaction with saccharides and mammalian cancer cells. J. Biomed. Mater. Res. A. 2009, 88A, 213–225.

[33] Liu, A.; Peng, S.; Soo, J. C.; Kuang, M.; Chen, P.; Duan, H. Quantum dots with phenylboronic acid tags for specific labeling of sialic acids on living cells. Anal. Chem. 2011, 83, 1124–1130.

[34] Otsuka, H.; Uchimura, E.; Koshino, H.; Okano, T.; Kataoka, K. Anomalous binding profile of phenylboronic acid with N-acetylneuraminic acid (Neu5Ac) in aqueous solution with varying pH. J. Am. Chem. Soc. 2003, 125, 3493–3502.

[35] Cheng, C.; Zhang, X.; Wang, Y.; Sun, L.; Li, C. Phenylboronic acid-containing block copolymers: Synthesis, self-assembly, and application for intracellular delivery of proteins. New J. Chem. 2012, 36, 1413–1421.

[36] Deshayes, S.; Cabral, H.; Ishii, T.; Miura, Y.; Kobayashi, S.; Yamashita, T.; Matsumoto, A.; Miyahara, Y.; Nishiyama, N.; Kataoka, K. Phenylboronic acid-installed polymeric micelles for targeting sialylated epitopes in solid tumors. J. Am. Chem. Soc. 2013, 135, 15501–15507.

[37] Liu, S.; Jones, L.; Gu, F. X. Development of mucoadhesive drug delivery system using phenylboronic acid functionalized poly(d,l-lactide)-b-Dextran nanoparticles. Macromol. Biosci. 2012, 12, 1622–1626.

[38] Shen, J.; Wang, Y.; Ping, Q.; Xiao, Y.; Huang, X. Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J. Controlled Release 2009, 137, 217–223.

[39] Vijay, A. K.; Sankaridurg, P.; Zhu, H.; Willcox, M. D. P. Guinea pig models of acute keratitis responses. Cornea 2009, 28, 1153–1159.

[40] Cole, N.; Hume, E. B. H.; Vijay, A. K.; Sankaridurg, P.; Kumar, N.; Willcox, M. D. P. In vivo performance of melimine as an antimicrobial coating for contact lenses in models of CLARE and CLPU. Invest. Ophthalmol. Vis. Sci. 2010, 5, 390–395.

[41] Diebold, Y.; Jarrin, M.; Saez, V.; Carvalho, E. L. S.; Orea, M.; Calonge, M.; Seijo, B.; Alonso, M. J. Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials 2007, 28, 1553–1564.

[42] Dursun, D.; Wang, M.; Monroy, D.; Li, D. Q.; Lokeshwar, B. L.; Stern, M. E.; Pflugfelder, S. C. A mouse model of keratoconjunctivitis sicca. Invest. Ophthalmol. Vis. Sci. 2002, 43, 632–638.

[43] Bromba, C.; Carrie, P.; Chui, J. K. W.; Fyles, T. M. Phenyl boronic acid complexes of diols and hydroxyacids. Supramol. Chem. 2009, 21, 81–88.

[44] Shiomori, K.; Ivanov, A. E.; Galaev, I. Y.; Kawano, Y.; Mattiasson, B. Thermoresponsive properties of sugar sensitive copolymer of N-isopropylacrylamide and 3-(acrylamido)phenylboronic acid. Macromol. Chem. Physic. 2004, 205, 27–34.

[45] Kitano, S.; Kataoka, K.; Koyama, Y.; Okano, T.; Sakurai, Y. Glucose-responsive complex-formation between poly(vinyl alcohol) and poly(n-vinyl-2-pyrrolidone) with pendent phenylboronic acid moieties. Makromol. Chem-Rapid. 1991, 12, 227–233.

[46] Wang, Y.; Zhang, X.; Han, Y.; Cheng, C.; Li, C. pH- and glucose-sensitive glycopolymer nanoparticles based on phenylboronic acid for triggered release of insulin. Carbohydr. Polym. 2012, 89, 124–131.

[47] Lee, D.; Shirley, S. A.; Lockey, R. F.; Mohapatra, S. S. Thiolated chitosan nanoparticles enhance anti-inflammatory effects of intranasally delivered theophylline. Resp. Res. 2006, 7, 112.

[48] Yuan, X.-B.; Li, H.; Yuan, Y. Preparation of cholesterol-modified chitosan self-aggregated nanoparticles for delivery of drugs to ocular surface. Carbohydr. Polym. 2006, 65, 337–345.

[49] Hermans, K.; Van Den Plas, D.; Schreurs, E.; Weyenberg, W.; Ludwig, A. Cytotoxicity and anti-inflammatory activity of Cyclosporine A loaded PLGA nanoparticles for ocular use. Pharmazie 2014, 69, 32–37.

[50] Shen, J.; Deng, Y.; Jin, X.; Ping, Q.; Su, Z.; Li, L. Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for Cyclosporine A: Improving in vivo ocular distribution. Int. J. Pharm. 2010, 402, 248–253.

[51] Aksungur, P.; Demirbilek, M.; Denkbas, E. B.; Vandervoort, J.; Ludwig, A.; Unlu, N. Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies. J. Controlled Release 2011, 151, 286–294.

[52] Basaran, E.; Yenilmez, E.; Berkman, M. S.; Buyukkoroglu, G.; Yazan, Y. Chitosan nanoparticles for ocular delivery of Cyclosporine A. J. Microencapsul. 2014, 31, 49–57.

[53] Dong, Y. C.; Feng, S. S. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 2004, 25, 2843–2849.

[54] Musumeci, T.; Ventura, C. A.; Giannone, I.; Ruozi, B.; Montenegro, L.; Pignatello, R.; Puglisi, G. PLA/PLGA nanoparticles for sustained release of docetaxel. Int. J. Pharm. 2006, 325, 172–179.

[55] Francis, M. F.; Lavoie, L.; Winnik, F. M.; Leroux, J.-C. Solubilization of cyclosporin A in Dextran-g-polyethyleneglycolalkyl ether polymeric micelles. Eur. J. Pharm. Biopharm. 2003, 56, 337–346.

[56] Aliabadi, H. M.; Mahmud, A.; Sharifabadi, A. D.; Lavasanifar, A. Micelles of methoxy poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization and controlled delivery of Cyclosporine A. J. Controlled Release 2005, 104, 301–311.

[57] Velluto, D.; Demurtas, D.; Hubbell, J. A. PEG-b-PPS diblock copolymer aggregates for hydrophobic drug solubilization and release: Cyclosporin A as an example. Mol. Pharm. 2008, 5, 632–642.

[58] Mondon, K.; Zeisser-Labouebe, M.; Gurny, R.; Moeller, M. Novel cyclosporin A formulations using MPEG-hexyl-substituted polylactide micelles: A suitability study. Eur. J. Pharm. Biopharm. 2011, 77, 56–65.

[59] Yang, W. Q.; Gao, X. M.; Wang, B. H. Boronic acid compounds as potential pharmaceutical agents. Med. Res. Rev. 2003, 23, 346–368.

[60] Toshida, H.; Nakayasu, K.; Kanai, A. Effect of cyclosporin A eyedrops on tear secretion in rabbit. Jpn. J. Ophthalmol. 1998, 42, 168–173.

[61] Stern, M. E.; Gao, J. P.; Siemasko, K. F.; Beuerman, R. W.; Pflugfelder, S. C. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp. Eye Res. 2004, 78, 409–416.